SCULLY, SCOTT, MURPHY & PRESSER A PROFESSIONAL CORPORATION

ATTORNEYS AT LAW

400 GARDEN CITY PLAZA, SUITE 300 GARDEN CITY, NEW YORK 11530-3319

ALLEN R. MORGANSTERN ALEK P. SZECSY STEPHEN A. YOUNG COUNSEL

ZHUANG YUAN TECHNICAL CONSULTANT

JOHN F. SCULLY STEPHEN D. MURPHY KENNETH L. KING

ANTHONY C. SCOTT (1931-1994) WILLIAM E. MCNULTY (1927-1993)

TELEPHONE: (516) 742-4343 FACSIMILE: (516) 742-4366 E-MAIL: intprop@ssmp.com

THOMAS SPINELLI ROBERT L. BERNSTEI MARVIN BRESSLER DERMOTT J. COOKE® RICHARD J. DANYKO BRADLEY M, MARAZAS SETH M. WEINFELD KEITH A. WELTSCH* YONGZHI YANG XIAOCHUN ZHU OH BAR ONLY

LEOPOLD PRESSER

FRANK S. DIGIGLIO PAUL J. ESATTO, JR.

JOHN S. SENSNY MARK J. COHEN EDWARD W. GROLZ

STEVEN FISCHMAN

PETER I. BERNSTEIN

*MD BAR ONLY *NC BAR ONLY

YONG LU LESLIE S. SZIVOS, PH.D. DAVID J. TORRENTE, J.D. PATENT AGENTS

DOMINICK A. TUCCIO TECHNICAL COUNSULTANT

> Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

> > USSN: 10/522,494 Re:

> > > Louis Schofield Our Docket: 18611

Dear Sirs:

The Filing Receipt for the above-identified patent application does not include the Assignment For Published Patent Application on the Filling Receipt. It should read as follows:

> **Assignment For Published Patent Application** The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia

March 15, 2006

as indicated on the enclosed pages. Please make the corrections and send us a corrected Filing Receipt.

SSM&P/tw Encl.



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1430 Alexandria, Virginia 22313-1450

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/522 494	09/06/2005	1615	6590	18611	24	83	12

CONFIRMATION NO. 4482

Leopold Presser Scully Scott Murphy & Presser 400 Garden City Plaza Suite 300 Garden City, NY 11530



FILING RECEIPT

OC000000018052339

Date Mailed: 02/17/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Louis Schofield, Gisborne, Victoria, AUSTRALIA;

Power of Attorney:

Leopold Presser--19827

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/AU03/00944 07/25/2003 which claims benefit of 60/398,607 07/26/2002

Foreign Applications

Projected Publication Date: 05/25/2006

Non-Publication Request: No

Early Publication Request: No

Title

Immunogenic compositions and diagnostic and therapeutic uses thereof

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filling receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

			·
FOR (REV	M PTO	0-1390 (Modified) U.S. PATENT AND TRADEM. OFFICE; U.S. DEPARTMENT OF COMMERCE 0004)	ATTOR .'S DOCKET NUMBER
,,,,,	T	RANSMITTAL LETTER TO THE UNITED STATES	18611
ļ		DESIGNATED/ELECTED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
	^^	INCERNING A SUBMISSION UNDER 35 U.S.C. 371	60/398,607
L		ATIONAL APPLICATION NO. INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
lin I	EKINA	PCT/AU2003/000944 25 July 2003	26 July 2002
		FINVENTION	
IMI	MUN	OGENIC COMPOSITIONS AND DIAGNOSTIC AND THEREFOLD INC.	SES THEREOF
		40	
e e		NT(S) FOR DO/EO/US CHOFIELD MAR 2 2 2006	
Appli	icant	herewith submits to the United States Designated/Elected Office (DS Paris The follo	wing items and other information:
1.	×	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371	
2.	. 🗆		•
3.	. 🗆		•
4.		The US has been elected (Article 31).	
5.	\boxtimes	A copy of the International Application as filed (35 U.S.C. 371 (c)(2))	
		a. $\ \square$ is attached hereto (required only if not communicated by the International	Bureau).
		b. 🗵 has been communicated by the International Bureau.	
		c. is not required, as the application was filed in the United States Receiving	Office (RO/US).
6.	\boxtimes	An English language translation of the International Application as filed (35 U.S.C. 3	71(c)(2)).
		a. is attached hereto.	
		b. 🛛 has been previously submitted under 35 U.S.C. 154(d)(4).	
7.	\boxtimes	Amendments to the claims of the International Application under PCT Article 19 (35)	` ' ' ''
		a. are attached hereto (required only if not communicated by the International	Bureau)
		b. have been communicated by the International Bureau.	
		c. have not been made; however, the time limit for making such amendments	has NOT expired.
	_	d. 🛮 have not been made and will not be made.	
8.		An English language translation of the amendments to the claims under PCT Article	19 (35 U.S.C. 371(c)(3)).
9. 10.		An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). An English language translation of the annexes to the International Preliminary Exam	ination Report under PCT
		Article 36 (35 U.S.C. 371 (c)(5)).	
11.	\boxtimes	A copy of the International Preliminary Examination Report (PCT/IPEA/409).	· · ·
12.	X	A copy of the International Search Report (PCT/ISA/210).	
ite	ms 1	3 to 23 below concern document(s) or information included:	
13.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.	*
14.		An assignment document for recording. A separate cover sheet in compliance with 3	7 CFR 3.28 and 3.31 is included.
15.		A FIRST preliminary amendment.	7 CFR 3.28 and 3.31 is included.
16.		A SECOND or SUBSEQUENT preliminary amendment.	· #
17.		A substitute specification.	<u> </u>
18.		A power of attorney and/or change of address letter.	₹ 7
19.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter	r.2 and 37 CFR 1.821 - 1.825.
20.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).	
21.		A second copy of the English language translation of the International Application und	
22.	X	Express Mail Label No. EV 213895745 US	COP
23.	X	Other items or information:	·
	C	Courtesy copy of PCT Application Twenty-Four (24) sheets of Formal Drawings Assignee: The Walter and Eliza Hall Institute of Medical Research, of Royal Parade, I	~

Jucket No.: 18611 U.S. DEPARTMENT OF COMMERC OMB No. 0651-0027 (mp.5/31/2002) Patent and Trademark Office POBA/REVO3 103079300 Tab settings -To the Director of the United States Patent and Trademark Office: Please record the attached original documents or copy thereof. 2. Name and address of receiving party(ies): 1. Name of conveying party(ies): Louis Schofield 9-6.05 The Walter and Eliza Hall Institute of Medical Research Address: Royal Parade, Parkville 3. Nature of conveyance: Assignment ☐ Merger City: Victoria ☐ Security Agreement ☐ Change of Name _ State/Prov.: Country: Australia Other _ Execution Date: May 20, 2005 Additional name(s) & address(es) attached? ☐ Yes ⊠ No 4. Application number(s) or patent numbers(s): If this document is being filed together with a new application, the execution date of the application is: Patent Application No. Filing date B. Patent No.(s) 10/522,494 January 26, 2005 Additional numbers attached? Yes No 5. Name and address of party to whom correspondence 6. Total number of applications and patents involved: concerning document should be mailed: Name: Peter I. Bernstein 7. Total fee (37 CFR 3.41):.....\$ 40.00 Registration No. 43,497 Enclosed - Any excess or insufficiency should be credited or debited to deposit account Address: Scully, Scott, Murphy & Presser ☐ Authorized to be charged to deposit account 400 Garden City Plaza, Suite 300 8. Deposit account number: 19-1013/SSMP City: Garden City ____ State/Prov.: NY ZIP: 11530 Country: USA (Attach duplicate copy of this page if paying by deposit account) DO NOT USE THIS SPACE 9. Statement and signature.

Total number of pages including cover sheet, attachments, and document: Mail documents to be recorded with required cover sheet information to:

Mail Stop Assignment Recordation Services

Director of the United States Patent and Trademark Office

P.O. Box 1450, Alexandria, VA 22313-1450 09/09/2005 ECOOPER 00000142 10522494

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy to

Signature

September 1, 2005

Date

of the original document.

Peter L Bernstein

Name of Person Signing

ASSIGNMENT

	LD, an Australian citizen of 185 Panorama Drive, Gisborne, Victoria 3	
hereinafter referred to improvements in In	as Assignor (collectively if more than one inventor is listed above), have invented centions and diagnostic and therapeutic use	rtain new and useful
the specification of whi	·	
(a) [] (b) []	was executed on even date herewith; was filed on as [] Application No [] Express Mail No., as Application No not yet known	or
(c) [x]	was described and claimed in PCT International Application PCT/AU2003/000 filed on 25 July 2003	and was amende
•	any) and/or under PCT Article 34 on (if any)	(if
AND WHEREAS, THE WALTER AN Parkville, Victoria 30	D ELIZA HALL INSTITUTE OF MEDICAL DESEARCH	yal Parade,
THE WALTER AN Parkville, Victoria 30 hereinaster referred to as	Assignee) desires to acquire the entire rights title and its	٧.
Parkville, Victoria 30 thereinafter referred to as espect to the United State NOW, THEREF ssignor hereby acknowle ansfer and set over, unto ates of America, and its ates of America and all a granted thereon and all reby authorizes and recoprovements to Assignee,	TD ELIZA HALL INSTITUTE OF MEDICAL RESEARCH, of Ro	ereby acknowledged s hereby sell, assign interest in the United cations in the United America which may nations; and Assignor

This 20^{74} day of MAY, 2005

Witness LACHLAN WILSON

Signature of

Louis SCHOFIELD

BEST AVAILABLE COPY